CJC-1295 No Dac 5mg Dosage Protocol
Contents
- Quickstart Highlights
- Dosing & Reconstitution Guide
- Standard / Gradual Approach (2 mL = ~2.5 mg/mL)
- Reconstitution Steps
- Supplies Needed
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Important Notes
- How This Works
- Potential Benefits & Side Effects
- Lifestyle Factors
- Injection Technique
- Recommended Source
- Important Note
- References
Quickstart Highlights
CJC-1295 No DAC is a synthetic analog of growth hormone–releasing hormone (GHRH) designed for laboratory investigation of endogenous growth hormone (GH) signaling pathways. It binds to GHRH receptors located in the anterior pituitary, initiating intracellular signaling that stimulates the release of growth hormone within controlled research environments.
Unlike DAC-modified versions, the No DAC formulation does not include a Drug Affinity Complex, meaning it does not bind to serum albumin. This results in a shorter activity window, making it suitable for research models focused on pulsatile GH release dynamics and time-sensitive endocrine signaling analysis.
CJC-1295 No DAC is available in both 5mg and 10mg vial options to accommodate varying research protocols.
Reconstitution & Dose Overview:
Add 2.0 mL bacteriostatic water → ~2.5 mg/mL concentration.
Typical daily range: 250–500 mcg, titrated gradually.
Easy measuring: 1 unit on a U‑100 insulin syringe = 0.01 mL ≈ 25 mcg.
Storage: Lyophilized: refrigerate 2–8 °C or freeze ≤−20 °C; after reconstitution, refrigerate and use within 1–2 weeks.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Basic / Advanced Approach (2 mL = ~2.5 mg/mL)
| Protocol | Daily Dose (mcg) | Units (per injection) | Volume (mL) |
|---|---|---|---|
| Basic | 250 mcg | 10 units | 0.1 mL |
| Advanced | 500 mcg | 20 units | 0.2 mL |
Frequency: 5 Times Per Week (Fasted)
You must take this peptide fasted. No food 2-3 hours before taking this peptide.
Preferably at bedtime to align with natural nocturnal GH pulsatility.
Reconstitution Steps
Draw 2.0 mL bacteriostatic water using a sterile syringe.
Inject slowly along the vial wall to avoid foaming.
Gently swirl/roll until dissolved; do not shake.
Label vial with date and concentration; refrigerate at 2–8 °C.
Use within 1–2 weeks; discard if cloudy or particulate appears.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Based on an 8–16 week protocol with gradual titration:
CJC-1295 NO DAC Vials (5 mg each):
8 weeks ≈ 2 vials
12 weeks ≈ 3 vials
16 weeks ≈ 4 vials
Insulin Syringes (U‑100):
1/day → 5/week
8 weeks: 40 syringes
12 weeks: 60 syringes
16 weeks: 80 syringes
Bacteriostatic Water (10 mL bottles): Use ~3 mL per vial
8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
12 weeks (3 vials): 6 mL → 1 × 10 mL bottle
16 weeks (4 vials): 8 mL → 1 × 10 mL bottles
Alcohol Swabs: One for vial + one for injection site each day
8 weeks: 80 swabs → 1 × 100-count boxes
12 weeks: 120 swabs → 2 × 100-count boxes
16 weeks: 160 swabs → 2 × 100-count boxes
Protocol Overview
A simplified outline of the once-weekly research approach.
- Goal: Stimulate natural GH release, elevate IGF‑1, support lean mass, metabolic health, and recovery.
- Schedule: Daily subcutaneous injections for 8–12 weeks; extendable to 16 weeks.
- Dose Range: 100–300 mcg, titrated gradually.
- Storage: Lyophilized refrigerated/frozen; reconstituted refrigerated; avoid repeated freeze-thaw.
Dosing Protocol
Example of a gradual weekly titration strategy:
Start: 250 mcg daily; increase ~50 mcg every 1–2 weeks.
Target: 250-500 mcg daily
Frequency: 5 Times per week, preferably at bedtime.
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Same time daily; rotate injection sites.
Storage Instructions
Maintaining proper storage conditions is essential for stability.
Lyophilized: Store at 2–8 °C; freeze ≤−20 °C for long-term storage.
Reconstituted: Refrigerate 2–8 °C; use within 1–2 weeks; avoid freeze-thaw.
Let vials reach room temperature before opening to prevent condensation.
Important Notes
Key considerations for consistency and safe handling:
Use a new sterile syringe for each injection; dispose properly in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to minimize irritation.
Inject slowly and hold a few seconds before removing needle.
Document doses and site rotation.
Administer on an empty stomach (fasted ≥2 hours) for optimal GH response.
How This Works
CJC-1295 NO DAC is a modified GHRH analog (Modified GRF 1–29) with four amino acid substitutions to enhance stability. It binds pituitary GHRH receptors, stimulating pulsatile endogenous GH secretion. The short half-life (~30 min) produces natural GH pulses, preserving physiologic feedback loops and minimizing risks of supraphysiologic GH exposure.
Potential Benefits & Side Effects
Benefits (from preclinical & clinical studies):
Pulsatile GH release, elevated IGF‑1.
Supports lean mass, reduces fat mass.
Enhances recovery, sleep quality, and energy levels.
Side Effects:
Generally mild; may include injection-site redness, swelling, transient flushing, or headache.
Lifestyle Factors
Supporting variables that may improve research consistency:
Follow a protein-rich, balanced diet.
Include resistance and aerobic training to support GH effects.
Prioritize sleep and manage stress.
Administer peptide fasted to maximize GH release.
Injection Technique
General guidance for subcutaneous administration:
- Clean the vial stopper and injection area with alcohol and allow to dry
- Gently pinch the skin and insert the needle at a 45–90° angle
- Inject slowly and steadily without aspirating
- Hold the needle in place for a few seconds before removing
- Rotate injection sites (abdomen, thighs, upper arms) to reduce irritation
Recommended Source
We recommend Fit Aminos for high-purity CJC-1295 research peptide products.
Why Fit Aminos?
- High-purity, lab-tested peptide batches with quality verification.
- Consistent handling and preparation processes designed to support reliable research protocols.
- Transparent sourcing and dependable fulfillment for research-grade compounds.
Important Note
This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment. CJC-1295 remains an investigational peptide with limited human clinical data. For research use only. Not for human consumption.
References
Wikipedia — Modified GRF (1–29): structure, amino acid substitutions, and pharmacokinetics
Provides an overview of Modified GRF (1–29), including its structure, key amino acid modifications, and pharmacokinetic profile.
Journal of Clinical Endocrinology & Metabolism (2006) — Teichman et al.: Prolonged stimulation of GH and IGF‑I by CJC-1295 in healthy adults. This study demonstrates that CJC-1295 significantly increases growth hormone and IGF‑1 levels in healthy adults.
American Journal of Physiology (2006) — Alba et al.: Once‑daily CJC-1295 normalizes growth in GHRH knockout mice
Research shows that daily administration of CJC-1295 restores normal growth patterns in GHRH-deficient mice. Highlights its role in regulating growth hormone pathways.
Journal of Clinical Endocrinology & Metabolism (2006) — Veldhuis et al.: Pulsatile GH secretion persists during continuous CJC-1295 stimulation. Findings indicate that CJC-1295 maintains natural pulsatile GH secretion even with continuous stimulation.
PMC — Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF‑1 Levels. This study explores how GH secretagogues increase IGF‑1 levels in hypogonadal men.